Franklin Resources Inc Argenx Se Transaction History

Franklin Resources Inc

$313 Billion
Q2 2024

A detailed history of Franklin Resources Inc transactions in Argenx Se stock. As of the latest transaction made, Franklin Resources Inc holds 136,222 shares of ARGX stock, worth $81.1 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

136,222

Previous 167,093 18.48%

Holding current value

$81.1 Million

Previous $65.8 Million 10.96%

% of portfolio

0.02%

Previous 0.02%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$356.01 - $451.55 $11 Million - $13.9 Million	-30,871 Reduced 18.48%	136,222 $58.6 Million
Q1 2024 May 13, 2024	SELL	$356.95 - $413.29 $2.55 Million - $2.95 Million	-7,133 Reduced 4.09%	167,093 $65.8 Million
Q4 2023 Feb 09, 2024	SELL	$338.91 - $506.01 $2.86 Million - $4.27 Million	-8,442 Reduced 4.62%	174,226 $66.3 Million
Q3 2023 Nov 13, 2023	SELL	$369.35 - $548.43 $23.5 Million - $34.9 Million	-63,643 Reduced 25.84%	182,668 $89.8 Million
Q2 2023 Aug 11, 2023	SELL	$360.14 - $422.58 $132,531 - $155,509	-368 Reduced 0.15%	246,311 $96 Million
Q1 2023 May 12, 2023	BUY	$334.23 - $403.65 $11.9 Million - $14.4 Million	35,574 Added 16.85%	246,679 $91.9 Million
Q4 2022 Feb 10, 2023	SELL	$342.17 - $402.31 $89,306 - $105,002	-261 Reduced 0.12%	211,105 $80 Million
Q3 2022 Nov 14, 2022	SELL	$343.2 - $395.75 $13.5 Million - $15.5 Million	-39,292 Reduced 15.68%	211,366 $74.6 Million
Q2 2022 Aug 11, 2022	SELL	$269.58 - $378.88 $163,904 - $230,359	-608 Reduced 0.24%	250,658 $95 Million
Q1 2022 May 13, 2022	BUY	$254.45 - $351.06 $29.5 Million - $40.7 Million	115,982 Added 85.73%	251,266 $79.2 Million
Q4 2021 Feb 11, 2022	SELL	$272.01 - $353.03 $2,992 - $3,883	-11 Reduced 0.01%	135,284 $47.4 Million
Q3 2021 Nov 12, 2021	BUY	$295.0 - $350.58 $146,910 - $174,588	498 Added 0.37%	135,295 $40.9 Million
Q2 2021 Aug 13, 2021	BUY	$257.11 - $319.92 $2.98 Million - $3.7 Million	11,574 Added 9.39%	134,797 $40.6 Million
Q1 2021 May 13, 2021	SELL	$268.3 - $380.31 $22.2 Million - $31.5 Million	-82,714 Reduced 40.16%	123,223 $33.9 Million
Q4 2020 Feb 10, 2021	SELL	$248.13 - $308.36 $4.06 Million - $5.05 Million	-16,381 Reduced 7.37%	205,937 $60.6 Million
Q3 2020 Nov 12, 2020	SELL	$215.51 - $272.51 $72.5 Million - $91.7 Million	-336,468 Reduced 60.21%	222,318 $58.4 Million
Q2 2020 Aug 13, 2020	SELL	$127.44 - $232.72 $2 Million - $3.65 Million	-15,669 Reduced 2.73%	558,786 $145 Million
Q1 2020 May 13, 2020	SELL	$108.83 - $165.23 $5.39 Million - $8.18 Million	-49,513 Reduced 7.94%	574,455 $75.7 Million
Q4 2019 Feb 12, 2020	BUY	$106.59 - $164.21 $11.1 Million - $17.2 Million	104,441 Added 20.1%	623,968 $100 Million
Q3 2019 Nov 14, 2019	BUY	$113.31 - $150.51 $25,268 - $33,563	223 Added 0.04%	519,527 $59.2 Million
Q2 2019 Aug 14, 2019	BUY	$115.0 - $141.58 $3.34 Million - $4.11 Million	29,001 Added 5.91%	519,304 $73.5 Million
Q1 2019 May 14, 2019	SELL	$98.85 - $134.59 $3.75 Million - $5.1 Million	-37,913 Reduced 7.18%	490,303 $61.2 Million
Q4 2018 Feb 12, 2019	SELL	$63.81 - $109.82 $4.63 Million - $7.96 Million	-72,505 Reduced 12.07%	528,216 $50.7 Million
Q3 2018 Nov 13, 2018	BUY	$75.5 - $96.63 $8.14 Million - $10.4 Million	107,800 Added 21.87%	600,721 $45.6 Million
Q2 2018 Aug 14, 2018	BUY	$74.84 - $100.16 $3.02 Million - $4.04 Million	40,321 Added 8.91%	492,921 $40.8 Million
Q1 2018 May 10, 2018	SELL	$56.95 - $85.19 $284,750 - $425,950	-5,000 Reduced 1.09%	452,600 $36.4 Million
Q4 2017 Feb 14, 2018	BUY	$22.57 - $63.56 $2.43 Million - $6.84 Million	107,600 Added 30.74%	457,600 $28.9 Million
Q3 2017 Nov 13, 2017	BUY	$19.81 - $22.61 $6.93 Million - $7.91 Million	350,000	350,000 $7.85 Million

Others Institutions Holding ARGX

# of Institutions

381

Shares Held

31.5M

Call Options Held

303K

Put Options Held

429K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $32.9B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

News

Stay updated on Franklin Resources Inc with notifications on news.

Account

Franklin Resources Inc Argenx Se Transaction History